Minimal Residual Disease in Acute Myelogenous Leukemia Is Predictive, Unless You Are Over Age 60 and Treated with Decitabine

Transplant Cell Ther. 2021 Mar;27(3):197-198. doi: 10.1016/j.jtct.2021.02.001. Epub 2021 Feb 5.
No abstract available

Publication types

  • Comment

MeSH terms

  • Azacitidine / adverse effects
  • Decitabine / therapeutic use
  • Humans
  • Leukemia, Myeloid, Acute* / drug therapy
  • Middle Aged
  • Neoplasm, Residual

Substances

  • Decitabine
  • Azacitidine